NCT00929396View on ClinicalTrials.gov

A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Tuberculosis
Interventions
BIOLOGICAL

50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)

o,5 mL suspension for injection x 2 with 2 months interval

BIOLOGICAL

50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)

o,5 mL suspension for injection x 2 with 2 months interval

Trial Locations (1)

2300

Leiden University Medical Centre, Leiden

All Listed Sponsors
lead

Statens Serum Institut

OTHER

NCT00929396 - A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers | Biotech Hunter | Biotech Hunter